ARIAD Honored with Gold Stevie® Awards as Pharmaceutical Company of the Year at 2013 American Busine
ARIAD Honored with Gold Stevie®Awards as Pharmaceutical Company of the Year at 2013 American Business Awardssm
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced that it was honored with two Gold Stevie® Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals. Harvey J. Berger, M.D., founder, chairman and chief executive officer of ARIAD, accepted the awards at the 11th Annual American Business Awards in Chicago last night. The American Business Awards are the nation's premier business awards program. All organizations operating in the United States are eligible to submit nominations - public and private, for-profit and non-profit, large and small.
"The recognition of ARIAD through these two Stevie Awards at the same time represents the culmination of more than twenty years of dedication to ARIAD's vision -- to transform the lives of cancer patients with breakthrough medicines," stated Dr. Berger. "All of our employees are to be commended for their contributions that led to ARIAD being named Company of the Year. Personally, I am humbled by the recognition as Pharmaceutical Executive of the Year by the American Business Awards."
Nicknamed the Stevies for the Greek word for "crowned," the trophies were presented to honorees during a gala event on Monday, June 17 at the Fairmont Chicago Millennium Park Hotel. More than 500 nominees and their guests attended. The presentations will be broadcast this week by the Business TalkRadio Network on Wednesday and Thursday nights.
More than 3,200 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.
"This year's American Business Awards was outsized in every way," said Michael Gallagher, Stevie Awards founder and president. "More entries and more judges than ever before, and I'd have to say the most impressive collection of nominations we've ever received. We congratulate all of this year's Stevie winners for their outstanding work."
Details about The American Business Awards and the lists of Stevie Award winners who were announced on June 17 are available at www.StevieAwards.com/ABA.
About the Stevie Awards
Stevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. A fifth program, the Asia-Pacific Stevie Awards, will debut this year. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com.
Sponsors and partners of The 2013 American Business Awards include the Business TalkRadio Network, Callidus Software, Citrix Online, Dynamic Research Corporation, Experian Consumer Services, John Hancock Funds, LifeLock, PetRays, and SoftPro.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
KEYWORDS: United States North America Illinois Massachusetts
The article ARIAD Honored with Gold Stevie® Awards as Pharmaceutical Company of the Year at 2013 American Business Awardssm originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.